Compare Campbell Soup Co. (CPB) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Quest Diagnostics Inc — how do they compare? Campbell Soup Co. trades at $19.21 (market cap $5.78B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 4.4× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Quest Diagnostics Inc for 56 Days on average.
| CPB | DGX | |
|---|---|---|
Market Cap | $5.78B | $25.48B |
Volume | 11,705,427 | 941,866 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $247.45 |
52-Week Low | $18.90 | $173.49 |
Typical Hold Time | 98 Days | 56 Days |
Enterprise Value | $12.83B | $31.23B |
Dividend Yield | 5.16% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.37, up 2.49% with bearish technical signals and mixed fundamentals. The company reported a Q4 2026 earnings miss but beat expectations in Q1 and Q2 2026. Recent developments include a 36% dividend cut to $0.25, workforce reductions, and a $500 million cost savings program. Revenue grew to $10.25B in 2025, but net margins compressed to 4.14% amid margin pressure.
Outlook remains challenging with weak FY2027 guidance and declining profitability trends. The stock offers a 5% dividend yield post-cut, but execution risks on cost savings and competitive pressures in the packaged food sector create headwinds. Analyst consensus is cautious with 58.62% Hold ratings and a $19.73 price target near current levels.
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
